Clinical Trial: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy
Study Status: Completed
Recruit Status: RECRUITING
Condition: Prostatic Neoplasms, Castration-Resistant
Study Type: INTERVENTIONAL
Official Title: Phase I Dose Escalation Study to Evaluate Tolerability and Safety of 225Ac-PSMA I&T in Patients With Metastatic Prostate Cancer
Brief Summary:
225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer.PSMA is overexpressed on prostate cancer cells.Actium-225 is an alpha emitting radionuclide.When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.
Read more